The prevalence of type 2 diabetes has increased dramatically over the last 2 decades and is predicted to double in a generation from 150 million in 2000 to 300 million by 2025 ([@B1]). The majority of this increase is taking place in developing countries undergoing nutritional transition and has a major impact on morbidity and health care resources ([@B2],[@B3]). Although the precise pathophysiology of type 2 diabetes remains unclear, it is largely thought to be caused by a combination of the interaction between multiple genes and environmental factors ([@B4]).

Single-nucleotide polymorphism (SNP) analysis of genome variation in large cohorts have led to the identification of several genes being implicated in the pathogenesis of type 2 diabetes, of which *TCF7L2* has been considered to be the most important to date ([@B5]). More recently, the first genome-wide association study using 207,097 SNP markers in Asian (Japanese) patients with type 2 diabetes and unrelated control subjects was conducted. This led to the finding that polymorphisms (rs2237895, rs2237897, and rs2283228) within a novel diabetes susceptibility gene, *KCNQ1*, were strongly associated with type 2 diabetes in the Japanese population ([@B6],[@B7]). Importantly, both studies corroborated these novel findings in populations of European and East Asian ancestry, including Chinese subjects living in Singapore ([@B6]). Notwithstanding these promising findings, it is unclear whether these polymorphisms are associated with quantitative traits relevant to the pathogenesis of type 2 diabetes, primarily impaired β-cell function and insulin resistance ([@B8]). Unoki et al. ([@B6]) did not report any association with β-cell function or insulin resistance, whereas only Yasuda et al. ([@B7]) found an association with β-cell function in Japanese (*P* = 0.021) and Finnish subjects (*P* = 0.024). To fill this knowledge gap, we aimed to investigate the association of these polymorphisms with *1*) insulin resistance and β-cell function and *2*) other quantitative metabolic risk phenotypes associated with type 2 diabetes within three different ethnicities (Chinese, Malay, and Asian Indian) living in Singapore.

RESEARCH DESIGN AND METHODS
===========================

The study used data from the cross-sectional population-based 1998 Singapore National Health Survey (NHS98; *n* = 4,723). Genotype data were available for 3,734 subjects comprising 2,520 Chinese, 693 Malay, and 521 Asian Indians. A total of 1,881 Chinese subjects with normal glucose tolerance (NGT) had previously served as the control subjects for the Singapore replication arm in our original report ([@B6]), whereas type 2 diabetes case subjects were from a separate study (the Singapore Diabetes Cohort Study). In this present study, all subjects (including subjects with NGT, impaired fasting glucose, impaired glucose tolerance \[IGT\], and type 2 diabetes) were derived from the NHS98 study. Details of the NHS98 survey have been previously described in greater detail ([@B9]). Briefly, this was a population-based, cross-sectional survey conducted between September and November in 1998. The reference population was 2.16 million Chinese, Malay, and Asian Indian Singapore residents aged between 18 and 69 years. The survey was based on the World Health Organization (WHO)-recommended model for field surveys of diabetes and other noncommunicable diseases and the WHO MONICA protocol for population surveys. The research protocol for NHS98 was approved by the Singapore General Hospital Institutional Review Board (\#54/2001).

Biological measures.
--------------------

Fasting blood samples were collected for glucose and insulin after an overnight fast of 10 h. All subjects underwent a 75-g oral glucose tolerance test except those taking oral hypoglycemic agents or insulin. Subjects were classified as having diabetes if they gave a history of diabetes or if their fasting glucose was \>7 mmol/l or 2-h post-challenge glucose \>11.1 mmol/l. Impaired fasting glycemia was defined as fasting glucose of 6--7 mmol/l and impaired glucose tolerance as 2-h post-challenge glucose of 7.8--11.1 mmol/l. Other measurements included the following: BMI and waist and hip circumference. Insulin resistance was estimated using the homeostasis model assessment method (HOMA-IR) ([@B10]). β-Cell function was assessed using the corrected insulin response at 120 min (CIR~120~) ([@B11]).

SNP genotyping.
---------------

Genotyping of four SNPs in intron 15 of *KCNQ1* rs2237897 (c\>T), rs2237895 (A\>C), rs2237892 (C\>T), and rs2283228 (A\>C) was performed using the TaqMan SNP genotyping assay (Applied Biosystems, Foster City, CA). Genotyping success rate for rs2237897, rs2237895, rs2237892, and rs2283228 was 92, 99, 92, and 87%, respectively. To assess reproducibility, 1% of samples were analyzed in duplicate; genotyping was 100% concordant for these samples.

Statistical analysis.
---------------------

Minor allele frequency, Hardy-Weinberg equilibrium, and linkage disequilibrium (LD; reported using *r*^2^) were estimated using Haploview ([@B12]). The distribution of glucose and insulin measures were skewed and therefore normalized by natural logarithmic transformation. Means were subsequently back transformed for presentation. Quantitative traits are presented as means and SDs. Linear regression analyses were performed to study the associations between diabetes-related traits with genotypic groups. Individuals were as assigned as 0/1/2 according to their number of minor alleles under an additive model of inheritance. There was no significant heterogeneity between the sexes (*P*\> 0.05), and subsequent analyses were performed with the sexes combined and adjusted for sex. Linear regression with adjustment for ethnicity was used to estimate the summary effect size of the SNPs in the combined sample from the three ethnic groups. Logistic regression was used to estimate the association between *KCNQ1* SNPs and type 2 diabetes. All analyses were stratified by ethnic group and adjusted for age, sex, and BMI (where appropriate). Analysis of association with β-cell function was further adjusted for insulin resistance ([@B13]). Analyses were performed using STATA (version 9.1 for Windows) ([@B14]).

RESULTS
=======

The anthropometric and biochemical characteristics of the participants are detailed in [Table 1](#T1){ref-type="table"}. Among these individuals, there was a higher prevalence of type 2 diabetes among the Malay and Asian Indian populations and a lower mean BMI and fasting glucose level among the Chinese population.

###### 

Clinical characteristics of the NHS98 study population by ethnicity

                                                                                              Chinese              Malay                Asian Indian
  ------------------------------------------------------------------------------------------- -------------------- -------------------- --------------------
  *n*                                                                                         2,520                693                  521
  Age                                                                                         37.9 ± 12.2          38.8 ± 12.7          40.5 ± 12
  \% male                                                                                     54.5                 52.4                 52.5
  BMI (kg/m^2^)                                                                               22.7 ± 3.7           25.6 ± 5             25.2 ± 4.8
  Waist-to-hip ratio                                                                          0.82 ± 0.07          0.83 ± 0.08          0.86 ± 0.08
  Waist circumference (cm)                                                                    78.1 ± 10.6          82.6 ± 12            85.2 ± 11.8
  Fasting glucose (mmol/l)[\*](#TF1-1){ref-type="table-fn"}[†](#TF1-2){ref-type="table-fn"}   5.53 (0--17.9)       5.89 (3.5--30)       6.01 (4.1--21.5)
  Fasting insulin (mmol/l)[\*](#TF1-1){ref-type="table-fn"}[†](#TF1-2){ref-type="table-fn"}   6.13 (0.2--576)      7.38 (0.7--83.4)     8.81 (1--119)
  HOMA-IR[\*](#TF1-1){ref-type="table-fn"}[†](#TF1-2){ref-type="table-fn"}                    1.47 (0.05--19.68)   1.86 (0.11--22.24)   2.2 (0.23--31.2)
  CIR~120~[\*](#TF1-1){ref-type="table-fn"}[†](#TF1-2){ref-type="table-fn"}                   0.79 (0.001--9.2)    0.76 (0.002--10.9)   0.84 (0.003--11.1)
  Glucose tolerance (%)                                                                                                                 
      NGT                                                                                     75.2                 60                   60.7
      IFG/IGT                                                                                 17.2                 25.6                 19.9
      Type 2 diabetes                                                                         7.6                  14.4                 19.4

Data are means ± SD unless otherwise stated. CIR~120~: 100 ×*I*~120~/\[*G*~120~× (*G*~120~− 70)\]. Units for insulin~120~(*I*^120^) are given in mmol/l and for glucose~120~(*G*~120~) in mg/dl.

\*Geometric mean (range) shown, due to skewed nature of data.

†Subjects taking diabetes medication were excluded (59 Chinese, 35 Malays, and 44 Asian Indians).

Allele frequency for rs2237897, rs2237895, rs2237892, and rs2283228 were similar between the Chinese and Malays but different in Asian Indians ([Table 2](#T2){ref-type="table"}). rs2237895 was in weak LD with rs2237897, rs2237892, and rs2283228 (*r*^2^ \< 0.25), whereas moderate LD was observed between rs2237897, rs2237892, and rs2283228 (Chinese:*r*^2^ = 0.56--0.79 Malay:*r*^2^ = 0.74--0.86, Asian Indian:*r*^2^ = 0.39--0.62) (Supplemental Fig. 1, found in an online-only appendix at <http://diabetes.diabetesjournals.org/cgi/content/full/db08-1138/DC1>). All SNPs in the Chinese and Malays were in Hardy-Weinberg equilibrium (*P*\> 0.05). In the Asian Indians, three of the SNPs that had low minor allele frequency (rs2237897, rs2237892, and rs2283228) were not in the Hardy-Weinberg equilibrium. Consequently, the results for the Asian Indians should be interpreted with caution.

###### 

Association of *KCNQ1* genetic variants with type 2 diabetes in the Chinese, Malay, and Asian Indian population in Singapore

                         Risk allele frequency   OR (95% CI)         *P*[\*](#TF2-1){ref-type="table-fn"}
  ---------------------- ----------------------- ------------------- --------------------------------------
  rs2237897 (**C**\>T)                                               
      Chinese            0.65                    1.50 (1.15--1.96)   0.003
      Malay              0.67                    1.32 (0.88--1.98)   0.183
      Asian Indians      0.95                    2.61 (1.01--6.74)   0.047
      Combined                                   1.48 (1.20--1.83)   3 × 10^−4^
  rs2237895 (A\>**C**)                                               
      Chinese            0.35                    1.09 (0.85--1.39)   0.496
      Malay              0.32                    1.39 (0.90--2.14)   0.14
      Asian Indians      0.39                    1.17 (0.81--1.70)   0.394
      Combined                                   1.16 (0.97--1.4)    0.111
  rs2237892 (**C**\>T)                                               
      Chinese            0.67                    1.39 (1.08--1.79)   0.011
      Malay              0.68                    1.28 (0.85--1.93)   0.245
      Asian Indians      0.95                    2.32 (0.87--6.22)   0.094
      Combined                                   1.38 (1.12--1.70)   0.002
  rs2283228 (**A**\>C)                                               
      Chinese            0.63                    1.22 (0.94--1.58)   0.135
      Malay              0.66                    1.39 (0.91--2.11)   0.124
      Asian Indians      0.92                    2.16 (0.98--4.74)   0.055
      Combined                                   1.31 (1.06--1.61)   0.012

Risk allele denoted in bold.

\**P* values adjusted for age, sex, BMI, and ethnicity (for combined analysis).

[Table 2](#T2){ref-type="table"} shows the association between *KCNQ1* SNPs with type 2 diabetes in the Chinese, Malay, and Asian Indian population in Singapore. Significant associations were observed in the Chinese, with rs2237897 showing the strongest effect: odds ratio (OR) 1.50 (1.15--1.96), *P* = 0.003. In the combined sample of the three ethnic groups, the risk alleles of rs2237897 (C), rs2237892 (C), and rs2283228 (A) were also associated with type 2 diabetes in our study, consistent with previous reports ([@B6],[@B7]). Of these, rs2237897 showed the strongest association (OR 1.48 \[1.20--1.83\], *P* = 0.0003). In the combined sample of only Chinese and Malays subjects, the association with rs2237897 remained significant (OR 1.45 \[1.16--1.81\], *P* = 0.001).

[Table 3](#T3){ref-type="table"} shows the association between *KCNQ1* SNPs with diabetes-related traits. The risk alleles for rs2237897, rs2237892, and rs2283228 showed statistically significant association with higher fasting glucose levels (*P* = 0.014, 0.011, and 0.034, respectively) and reduced CIR~120~(*P* = 0.007, 0.013, and 0.014, respectively) in the Chinese population. After restricting to subjects without diabetes, the association remained significant with CIR~120~(*P* = 0.011, 0.020, and 0.015, respectively; online appendix Table 1). A similar trend was observed among the Malays and Asian Indians, although the associations did not reach statistical significance, possibly because of the limited sample sizes for these minority ethnic groups. In the combined analysis, rs2237897 and rs2237892 were significantly associated with fasting glucose levels (*P* = 0.029 and *P* = 0.021, respectively), whereas rs2237897, rs2237892, and rs2283228 were significantly associated with lower β-cell function (CIR~120~) (*P* = 0.013, 0.021, and 0.020, respectively). These SNPs also showed associations with BMI in the Malay population and waist-to-hip ratio in Asian Indians. However, these associations were no longer statistically significant in the combined analysis. Based on a risk allele frequency of between 0.3 and 0.6, power calculations estimate that the combined sample provided 90% power to detect a 10% change in the examined traits.

###### 

Association with *KCNQ1* with diabetes-related traits

  Number of risk alleles                                                                                                             Chinese   *P*(adjusted for age and sex)   Malay   *P*(adjusted for age and sex)   Asian Indian   *P*(adjusted for age and sex)   Combined   *P*(adjusted for age and sex)                                                  
  ---------------------------------------------------------------------------------------------------------------------------------- --------- ------------------------------- ------- ------------------------------- -------------- ------------------------------- ---------- ------------------------------- ------ ----------- ------ ----------- -------- -----------
  **rs2237897 (C\> T)**                                                                                                                        *n* = 2,291                                                                            *n* = 638                                                                         *n* = 489                               
      BMI (kg/m^2^)                                                                                                                  23.5      23.5                            23.4    0.566                           26.4           25.4                            24.5       **0.001**                       23.4   23.9        24.3   0.477       −0.073   0.568
      WHR                                                                                                                            0.87      0.87                            0.87    0.382                           0.88           0.88                            0.87       0.227                           0.86   0.88        0.90   **0.036**   0.001    0.400
      Fasting glucose (mmol/l)[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                      5.58      5.63                            5.68    **0.014**                       5.76           5.80                            5.83       0.252                           5.37   5.57        5.78   0.209       0.051    **0.029**
      Fasting insulin (mmol/l)[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                      6.45      6.44                            6.43    0.517                           7.25           6.83                            6.43       0.846                           6.49   7.44        8.52   0.290       −0.064   0.576
      HOMA-IR[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                                       1.60      1.61                            1.62    0.236                           1.87           1.77                            1.67       0.623                           1.55   1.84        2.17   0.211       −0.002   0.280
      Cumulative insulin response[\*](#TF3-1){ref-type="table-fn"}[†](#TF3-2){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}   0.83      0.76                            0.70    **0.007**                       0.80           0.76                            0.71       0.322                           1.18   1.08        0.99   0.820       −0.060   **0.013**
  **rs2237895**(A\>**C**)                                                                                                                      *n* = 2,520                                                                            *n* = 693                                                                         *n* = 521                               
      BMI (kg/m^2^)                                                                                                                  23.4      23.5                            23.6    0.269                           25.4           25.0                            24.5       0.128                           24.7   24.6        24.5   0.786       0.108    0.359
      WHR                                                                                                                            0.87      0.87                            0.87    0.137                           0.88           0.87                            0.87       0.123                           0.90   0.90        0.90   0.562       0.002    0.146
      Fasting glucose (mmol/l)[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                      5.61      5.64                            5.67    0.237                           5.78           5.80                            5.82       0.528                           5.63   5.71        5.80   0.160       0.034    0.271
      Fasting insulin (mmol/l)[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                      6.45      6.40                            6.34    0.241                           6.86           6.76                            6.66       0.687                           8.56   8.72        8.87   0.474       −0.046   0.259
      HOMA-IR[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                                       1.61      1.60                            1.59    0.375                           1.77           1.75                            1.74       0.571                           2.14   2.20        2.27   0.297       −0.005   0.400
      Cumulative insulin response[\*](#TF3-1){ref-type="table-fn"}[†](#TF3-2){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}   0.76      0.73                            0.70    0.187                           0.84           0.76                            0.69       0.240                           1.22   1.07        0.94   0.071       −0.053   0.218
  **rs2237892**(**C**\>T)                                                                                                                      *n* = 2,327                                                                            *n* = 642                                                                         *n* = 474                               
      BMI (kg/m^2^)                                                                                                                  23.6      23.5                            23.4    0.707                           26.2           25.4                            24.6       **0.003**                       23.9   24.1        24.3   0.619       −0.069   0.731
      WHR                                                                                                                            0.87      0.87                            0.87    0.584                           0.88           0.87                            0.87       0.401                           0.87   0.88        0.89   0.064       0.000    0.623
      Fasting glucose (mmol/l)[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                      5.55      5.60                            5.66    **0.011**                       5.72           5.74                            5.76       0.163                           5.49   5.61        5.73   0.460       0.049    **0.021**
      Fasting insulin (mmol/l)[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                      6.42      6.42                            6.42    0.460                           7.42           6.92                            6.45       0.585                           6.81   7.58        8.44   0.342       −0.077   0.514
      HOMA-IR[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                                       1.58      1.60                            1.61    0.207                           1.90           1.77                            1.66       0.893                           1.59   1.84        2.13   0.310       −0.005   0.244
      Cumulative insulin response[\*](#TF3-1){ref-type="table-fn"}[†](#TF3-2){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}   0.85      0.78                            0.72    **0.013**                       0.88           0.84                            0.80       0.311                           1.13   1.09        1.05   0.937       −0.056   **0.021**
  **rs2283228**(**A**\>C)                                                                                                                      *n* = 2,215                                                                            *n* = 586                                                                         *n* = 450                               
      BMI (kg/m^2^)                                                                                                                  23.4      23.4                            23.4    0.669                           25.8           25.2                            24.6       **0.011**                       23.2   24.1        24.9   0.078       −0.015   0.800
      WHR                                                                                                                            0.87      0.87                            0.87    0.774                           0.88           0.88                            0.87       0.399                           0.87   0.88        0.90   **0.011**   0.001    0.863
      Fasting glucose (mmol/l)[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                      5.57      5.61                            5.65    **0.034**                       5.66           5.73                            5.80       0.072                           5.60   5.69        5.79   0.672       0.048    0.056
      Fasting insulin (mmol/l)[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                      6.26      6.35                            6.45    0.172                           7.31           6.83                            6.38       0.437                           6.79   7.78        8.93   0.257       0.027    0.216
      HOMA-IR[\*](#TF3-1){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}                                                       1.55      1.58                            1.62    0.071                           1.86           1.75                            1.65       0.844                           1.69   1.96        2.28   0.284       0.022    0.095
      Cumulative insulin response[\*](#TF3-1){ref-type="table-fn"}[†](#TF3-2){ref-type="table-fn"}[‡](#TF3-3){ref-type="table-fn"}   0.83      0.77                            0.71    **0.014**                       0.90           0.82                            0.76       0.109                           1.13   1.06        0.99   0.809       −0.060   **0.020**

Risk allele is shown in bold. Combined estimates were obtained using linear regression with adjustment for ethnicity.

\*Additionally adjusted for BMI and excluding subjects taking diabetic medication (59 Chinese, 35 Malays, and 44 Asian Indians).

†Additionally adjusted for insulin resistance (HOMA-IR).

‡Values were log-transformed to improve normality in regression analysis, and adjusted means were subsequently back-transformed. WHR, waist-to-hip ratio.

DISCUSSION
==========

Polymorphisms within *KCNQ1* have recently been shown to be strongly associated with an increased risk of type 2 diabetes in the East Asian and European populations ([@B6],[@B7]). Of the three polymorphisms within *KCNQ1* previously described, rs2237897 appeared to have the strongest association with type 2 diabetes ([@B6]), whereas another study reported the strongest association with rs2237892 ([@B7]). Consistent with these findings, we found that both these SNPs were significantly associated with type 2 diabetes in the combined analysis of three ethnic groups. In addition, the presence of the risk allele for *KCNQ1* variants rs2237897, rs2237892, and rs2283228 were associated with increased fasting glucose level and decreased β-cell function in the Chinese population and combined sample. This is in agreement with the study by Yasuda et al. ([@B7]), which reported an association of these *KCNQ1* variants with β-cell function. Together, these findings corroborate the hypothesis that the role of this protein in the pathogenesis of type 2 diabetes is likely mediated through its effects on the pancreatic β-cell, although there is still a possibility that these polymorphisms may increase the risk of type 2 diabetes through regulation of nearby genes. In contrast, there was no association between rs2237895 with any diabetes-related traits, specifically highlighting the importance of the polymorphisms rs2237897, rs2237892, and rs2283228 (which are in moderate LD) in increasing the risk of developing type 2 diabetes. Further fine mapping of SNPs in *KCNQ1*, especially within the LD block containing rs2237897 and rs2237892, may allow the identification of the causal variant.

*KCNQ1* is located on 11p15.5, which encodes the pore-forming α-subunit of the I~KS~ K^+^channel, which is expressed mainly in the heart and, to a lesser extent, the inner ear, stomach, small and large intestine, liver, and kidney. *KCNQ1* is also expressed in the pancreas, where it is coexpressed with products of other regulators such as *KCNE1*, which may alter its biophysical characteristics and role ([@B15]). As such, it is plausible that polymorphisms within the *KCNQ1* gene alter the properties and role of the I~KS~ K^+^channel, causing decreased pancreatic β-cellfunction and insulin production, leading eventually to hyperglycemia.

Whereas we do appreciate that the associations observed in the Chinese do not represent an independent replication, since the controls used are largely the same as those in the study by Unoki et al. ([@B6]), we have provided data on Malays and Indians and, in our opinion, it was reassuring that similar trends for an effect of these three polymorphisms on association with type 2 diabetes, fasting glucose, and β-cell function were also observed in the Malay and Asian Indian subjects, even though their limited numbers certainly resulted in a reduction of study power. Although associations with BMI in Malays and waist-to-hip ratio in Asian Indians were found, the smaller sample sizes for these ethnic groups, together with the fact that these observations were not found in other ethnic groups, inevitably led us to be cautious in interpreting these findings. One caveat of this study is that we only examined the SNPs, which showed the strongest association, identified by Unoki et al. ([@B6]) and Yasuda et al. ([@B7]). Although the Chinese show strong and consistent associations with these SNPs, the association among Malays and Asian Indians is less clear. Further fine mapping of the *KCNQ1* locus, for instance, through deep DNA resequencing may allow the identification of population-specific causative variants.

The use of CIR~120~represented a limitation of our study, since it only served as an approximate measure of β-cell function, which may be better assessed using the CIR~30~. Thus, if CIR~30~measurements were available, the positive associations that had been observed in our study may be further strengthened. It has also been suggested that CIR~120~could inadvertently capture information on additional aspects of glucose intolerance instead of insulin secretion alone. The previous finding of the association between CIR~30~with KCNQ1 SNPs, in nondiabetic European subjects of the Botnia prospective study during their follow-up visit (*P* = 0.024) ([@B7]), however, appeared to corroborate our hypothesis that these SNPs may exert their effect on type 2 diabetes through an effect on insulin secretion.

In conclusion, the risk alleles of rs2237897, rs2237892, and rs2283228 within the *KCNQ1* gene are associated with decreased pancreatic β-cell function and fasting glucose levels, suggesting that the impact of these polymorphisms on the risk of type 2 diabetes may be mediated through an impact on β-cell function rather than insulin resistance. Further studies will be useful to replicate these promising findings and to fully delineate the role of *KCNQ1* and its related pathways in the pathogenesis of type 2 diabetes.

Supplementary Material
======================

###### Online-Only Appendix

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was funded by the Singapore National Medical Research Council (NMRC/1115/2007).

No potential conflicts of interest relevant to this article were reported.
